Drug Search Results
More Filters [+]

YH-14755

Alternative Names: yh-14755, yh14755, yh 14755
Latest Update: 2018-10-03
Latest Update Note: Clinical Trial Update

Product Description

For dyslipidemia and Type II Diabetes

Mechanisms of Action: AMPK Binder,HMG-CoA Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Yuhan
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for YH-14755

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Dyslipidemia|Type 2 Diabetes

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

YH14755-301

P3

Completed

Type 2 Diabetes|Dyslipidemia

2017-07-07

60%

YH14755-102

P1

Completed

Healthy Volunteers

2014-09-01

Recent News Events

Date

Type

Title